Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 09:00 ET | Source: CohBar, Inc.

CohBar Confirms Anti-fibrotic Effect of a Novel Peptide in a Therapeutic Model of Idiopathic Pulmonary Fibrosis

MENLO PARK, Calif., Dec. 16, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related...